

<b>LIST OF REFERENCES CITED BY APPLICANT</b> (Use separate sheets if necessary)	ATTY DOCKET NO.	APPLICATION NO
	6750-214-999	10/687,035
	APPLICANT Albone <i>et al.</i>	
	FILING DATE October 15, 2003	GROUP To be assigned

### U.S. PATENT DOCUMENTS

*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
A01	4,921,790	5/1/90	O'Brien			
A02	5,059,680	10/22/91	Davis <i>et al.</i>			
A03	5,858,361	1/12/99	Wagner <i>et al.</i>			
A04	5,976,818	11/2/99	O'Brien			
A05	6,241,985	6/5/01	Madiyalakan <i>et al.</i>			
A06	6,468,546	10/22/02	Mitcham <i>et al.</i>			
A07	6,488,931	12/3/02	Mitcham <i>et al.</i>			
A08	6,528,253	3/4/03	Mitcham <i>et al.</i>			
A09	6,699,664	3/2/04	Mitcham <i>et al.</i>			
A10	6,670,463	12/30/03	Mitcham <i>et al.</i>			
A11	20020022591	2/21/02	Algate <i>et al.</i>			
A12	20020119158	8/29/02	Algate <i>et al.</i>			
A13	20030008299	1/9/03	Algate			
A14	20030091580	5/15/03	Mitcham <i>et al.</i>			
A15	20030124140	7/3/03	Bangur <i>et al.</i>			
A16	20030165504	9/4/03	Retter <i>et al.</i>			

### FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION
						YES      NO
A17	WO0036107	6/22/00	PCT			
A18	WO0206317	1/24/02	PCT			
A19	WO0157207	8/9/01	PCT			
A20	WO04005470	1/15/04	PCT			

### OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)

A21	Bast <i>et al.</i> (1981) "Reactivity of a Monoclonal Antibody with Human Ovarian Cancer". <i>J. Clin Invest</i> 68(5): 1331-37.
A22	Boshell <i>et al.</i> (1992) "The Product of the Human MUC1 Gene When Secreted by Mouse Cells Transfected With the Full-Length cDNA Lacks Cytoplasmic Tail". <i>Biochem and Biophys Res. Comm</i> 185(1):1-8.
A23	Frailes <i>et al.</i> (1993) "Purification and Characterization of the CA 125 Tumor-Associated Antigen From Human Ascites". <i>Tumour Biol.</i> 1993;14(1):18-29.
A24	Gadducci <i>et al.</i> (1992) : "The Concomitant Determination of Different Tumor Markers in Patients with Epithelial Ovarian Cancer and Benign Ovarian Masses: Relevance for Differential Diagnosis", <i>Gynecol Oncol.</i> 44(2):147-54.
A25	Hovig <i>et al.</i> (2001) "CA125: The End of the Beginning" <i>Tumor Bio.</i> 22:345-47.
A26	Hu <i>et al.</i> (2003) "Discovery and Validation of New Molecular Targets of Ovarian Cancer" <i>Current Opinion in Molecular Therapeutics.</i> 5(6):625-630.
A27	Kabawat <i>et al.</i> (1983) "Immunopathologic Characterization of a Monoclonal Antibody That Recognizes Common Surface Antigens of Human Ovarian Tumors of Serous, Endometrioid, and Clear Cell Types", <i>Am. J. Clin. Pathol.</i> 79:98-104

	A28	Lightenberg <i>et al.</i> (1992) "Cell-Associated Episialin Is a Complex Containing Two Proteins Derived From A Common Precursor" <i>The Journal of Biol. Chem.</i> .. 267(9):6171-77.
	A29	Madiyalakan <i>et al.</i> (1997) "Ovarex MAb-B43.13:IFN-Gamma Could Improve the Ovarian Tumor Cell Sensitivity to CA125-Specific Allogenic Cytotoxic T Cell" <i>Hybridoma</i> 16(1): 41-5.
	A30	Maeda <i>et al.</i> (2004) "Solution Structure of the SEA Domain From the Murine Homologue of Ovarian Cancer Antigen CA125 (MUC16)" <i>The Journal of Biol. Chem.</i> .. 279(13): 13174-13182.
	A31	Noujaim <i>et al.</i> (2001) "Induction of CA125-Specific B and T Cell Responses in Patients Injected With MAb-B43.13-- Evidence for Antibody-Mediated Anti-processing and Presentation of CA125 <i>in Vivo</i> " <i>Cancer Biother. Radiopharm</i> 16(3): 187-203.
	A32	Nustad <i>et al.</i> (1996) "Specificity and Affinity of 26 Monoclonal Antibodies Against the CA 125 Antigen: First Report From the ISOBM TD-1 Workshop. International Society for Oncodevelopmental Biology and Medicine" <i>Tumour Biol.</i> 17(4): 196-219.
	A33	Nustad <i>et al.</i> (2002) "Epitopes on CA 125 From Cervical Mucus and Ascites Fluid and Characterization of Six New Antibodies. Third report from the ISOBM TD-1 workshop" <i>Tumour Biol.</i> 23(5): 303-314.
	A34	O'Brien <i>et al.</i> (2001) "The CA125 Gene: An Extracellular Superstructure Dominated by Repeat Sequences" <i>Tumor Bio.</i> 22:348-366.
	A35	O'Brien <i>et al.</i> (2002) "The CA125 Gene: A Newly Discovered Extension of the Glycosylated N-Terminal Domain Doubles the Size of This Extracellular Superstructure" <i>Tumor Bio.</i> 23:154-169.
	A36	Saga <i>et al.</i> (1990) "Construction of an Immunoradiometric Assay for Ovarian Cancer Antigen CA125 Recognizing Different Antigenic Determinant" <i>ACTA Obstet Gynecol. Scand.</i> 69(2):175-81.
	A37	Saga <i>et al.</i> (1990) "An Antibody-Tumor Model for the Targeting of CA125-Producing Gynecologic Malignancies" <i>Jpn J. Cancer Res.</i> .. 81(11):1141-48.
	A38	Yin <i>et al.</i> (2001) "Molecular Cloning of the CA125 Ovarian Cancer Antigen" <i>The Journal of Biol. Chem.</i> 276(29):27371-375.

EXAMINER		DATE CONSIDERED	4/24/06
----------	---	-----------------	---------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

		ATTY DOCKET NO. 6750-214-999	APPLICATION NO 10/687,035
LIST OF REFERENCES CITED BY APPLICANT <i>O P E</i> (Use several sheets if necessary)		APPLICANT Albone et al.	
		FILING DATE October 15, 2003	GROUP 1632

NOV 29 2004  
PATENT & TRADEMARK OFFICE, U.S.A.

## U.S. PATENT DOCUMENTS

*EXAMINER INITIALS	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
<i>JH</i>	B01 5,693,762	12/2/97	Queen et al.			


## FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	YES	NO
<i>JH</i>	B02	International Search Report of PCT/US03/32945	8/25/04	PCT					
	B03	WO04005470	1/15/04	PCT					

## OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)

<i>JH</i>	B04:	Andersson, et al., 1999 "Biokinetics of the Monoclonal Antibodies MOv 18, OV 185 and OV 197 Labelled with <sup>125</sup> I According to the m-MeATE Method or the Iodogen Method in Nude Mice with Ovarian Cancer Xenografts", <i>ACTA Oncologica</i> , 38(3) 323-328.
	B05:	Bouvier, et al., 1988 "Serum Levels of Tumor Markers and Presence of Human Antimouse Antibodies: Implications for Diagnosis and Treatment with Radiolabeled Monoclonal Antibodies", <i>Cancer Detection and Prevention</i> , 13: 251-262.
	B06:	Chatal, et al., 1989 "Biodistribution of Indium-111-Labeled OC 125 Monoclonal Antibody Intraperitoneally Injected Into Patients Operated On for Ovarian Carcinomas", <i>Cancer Research</i> , 49: 3087-3094.
	B07:	Cuesta, et al., 1999 "Tissue Quantifications of CA 125 in Epithelial Ovarian Cancer", <i>The International Journal of Biological Markers</i> , 14(2): 106-114.
	B08:	Gaetje, et al., 1999 "Ovarian Cancer Antigen CA 125 Enhances the Invasiveness of the Endometriotic Cell Line EEC 145", <i>J. Soc. Gynecol. Invest.</i> , 6(5): 278-281.
	B09:	Haisma, et al., 1987 "Antibody-Antigen Complex Formation Following Injection of OC125 Monoclonal Antibody In Patients With Ovarian Cancer", <i>Int. J. Cancer</i> , 40: 758-762.
	B10:	Imai, et al., 1991 "Monoclonal Antibodies Against CA125-Bearing Antigenic Molecule Fragments; reactivity with Mucinous Ovarian Tumours and Lung Cancers", <i>Molecular and Cellular Probes</i> , 5: 55-63.
	B11:	Kalofonos, et al., 1999 "Radioimmunoscintigraphy In Patients With Ovarian Cancer", <i>ACTA Oncologica</i> , 38(5): 629-634.
	B12:	Kobayashi et al., 1993 "A Human/Mouse Chimeric Monoclonal Antibody Against CA125 for Radioimmunoimaging of Ovarian Cancer", <i>Cancer Immunol. Immunother.</i> , 37: 143-149.
	B13:	Markman, Maurie 1997, "The Role of CA-125 in the Management of Ovarian Cancer", <i>The Oncologist</i> , 2: 6-9.
	B14:	Maher, et al., 1992 "Human Antibody Response to the Intravenous and Intraperitoneal Admoinistration of the F(ab') <sub>2</sub> Fragment of the OC125 Murine Monoclonal Antibody", <i>Journal of Immunotherapy</i> , 11:56-66.
	B15:	National Comprehensive Cancer Network Practice Guideline sin Oncology Version 1 2002 "Ovarian cancer Guideline"
	B16:	Nyhus, et al., 2001 "IgG-Recognizing Shed Tumor-Assocaited Antigens Can Promote Tumor Invasion and Metastasis", <i>Cancer Immunol. Immunother.</i> , 50: 361-372.
	B17:	Osmers, et al., 1997 "Does an Immunoscintigraphy With OC 125 Affect the Prognosis of Ovarian Cancer?", <i>Eur J. Gynaecol. Oncol.</i> , 18(3): 177-182.
	B18:	Pimm, et al. 1995 "Circulating Antigen: Bad or Good for Immunoscintigraphy?" <i>Nuel Med. Biol.</i> , 22(2): 137-145
	B19:	Reinartz, et al., 2000 "Immunological Properties of a Single-Chain Fragment of the Anti-Idiotypic Antibody ACA125", <i>Cancer Immunol. Immunother.</i> , 49: 186-192.
	B20:	Reinsberg, et al., 1994 "False Changes in CA125 Levels In Ovarian Cancer Patients After Infusion of OC 125 Fragments For Diagnostic and Therapeutic Purpose", <i>Arch Gynecol Obstet.</i> , 255: 9-18.

/ LBG/	B21	Rustin, et al., 2004 "Use of CA-125 In Clinical Trial Evaluation of New Therapeutic Drugs For Ovarian Cancer", <i>Clinical Cancer Research</i> , 10: 3919-3926.
/ LBG/	B22	Seelenmeyer, et al., 2002 "The Cancer Antigen CA125 Represents A Novel Counter Receptor For Galectin-1" <i>Journal of Cell Science</i> , 116(7): 1305-1318.
/ LBG/	B23	Zeimet, et al., 1997 "Modulation of CA-125 Release By Inflammatory Cytokines In Human Peritoneal Mesothelial and Ovarian Cancer Cells", <i>Anticancer Research</i> , 17: 3129-3132.

EXAMINER		DATE CONSIDERED	4/24/06
<p>*EXAMINER: Initial if reference considered; whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</p>			



**LIST OF REFERENCES CITED BY APPLICANT**  
(see several sheets if necessary)

ATTY DOCKET NO.  
6750-214-999

APPLICATION NO  
10/687,035

APPLICANT  
Albone et al.

FILING DATE  
October 15, 2003

GROUP  
To be assigned

**U.S. PATENT DOCUMENTS**

*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
C01	2003-0104442 A1	6/5/03	Lloyd, et al.			
C02	2004-0127401 A1	7/1/04	O'Brien			

**FOREIGN PATENT DOCUMENTS**

	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	YES	NO
C03	EP 1256354	11/13/02	EPO					
C04	WO02007783	1/31/02	PCT					
C05	WO02083866	10/24/02	PCT					
C06	WO02092836	11/21/02	PCT					
C07	WO04045553	6/3/04	PCT					
C08	WO03076473	9/18/03	PCT					
C09	WO03076465	9/18/03	PCT					


**OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)**

C10	Beck, et al. (1994) "In Vitro Activity of Immunoconjugates Between Cisplatin and an Anti-CA125 Monoclonal Antibody on Ovarian Cancer Cell Lines", <i>Cell Biophysics</i> , 24(25): 163-173.
C11	Beck, et al. (1998) "CA 125 Production and Release By Ovarian Cancer Cells In Vitro", <i>Int. J. Biol. Markers</i> , 13(4): 200-206 163-173.
C12	Byrd, et al. (2004) "Mucins and Mucin Binding Proteins in Colorectal Cancer", <i>Cancer and Metastasis Reviews</i> , 23(1/2): 77-99.
C13	Candido, et al. (2003) "CA 125 and Vascular Endothelial Growth Factor in the Differential Diagnosis of Epithelial Ovarian Tumors", <i>Gynecologic and Obstetric Investigation</i> , 54(3): 132-136.
C14	Chang, et al. (2002) "Assessment of Plasma DNA Levels, Allelic Imbalance, and CA 125 as Diagnostic Tests for Cancer", <i>Journal of the National Cancer Institute</i> , 94(22): 1697-1703.
C15	Davis, et al. (1986) "Characterization of the CA125 Antigen Associated With Human Epithelial Ovarian Carcinomas", <i>Cancer Research</i> , 46(12 Pt 1): 6143-6148.
C16	Evans, et al. (2003) "Oregovomab", <i>American Journal of Cancer(Auckland, New Zealand)</i> , 2(2): 125-133.
C17	Fendrick, et al. (1997) "CA125 Phosphorylation Is Associated With Its Secretion From the WISH Human Amnion Cell Line", <i>Tumor Biology</i> , 18: 278-289.
C18	Guppy, et al. (2002) "CA125 Response: Can It Replace the Traditional Response Criteria in Ovarian Cancer", <i>The Oncologist</i> , 7: 437-443.
C19	Hu, et al. (2003) "Expression of Mucins and Cytokeratins In Ovarian Cancer Cell Lines", <i>Current Opinion in Molecular Therapeutics</i> , 5(6): 625-630.
C20	Imbert-Marcille, et al. (1994) "Modulation of Associated Ovarian Carcinoma Antigens by 5 Cytokines Used As Single Agents Or In Combination", <i>Int. J. Cancer</i> , 57: 392-398.
C21	Kabawat, et al. (1983) "Immunopathologic Characterization of a Monoclonal Antibody That Recognizes Common Surface Antigens of Human Ovarian Tumors of Serous, Endometrioid, and Clear Cell Types", <i>Am J. Clin. Pathol.</i> , 79(1): 98-104.
C22	Lamerz, Rolf. (1998) "34.4 CA 125", <i>Gastrointestinal Cancer Antigens</i> , 34.4: 969-972.
C23	Lloyd, et al. (1997) "Isolation and Characterization of Ovarian Cancer Antigen CA 125 Using a New Monoclonal Antibody (VK-8): Identification As A Mucin-Type Molecule", <i>Int. J. Cancer</i> , 71: 842-850.
C24	Lloyd, et al. (2001) "Synthesis and Secretion of the Ovarian Cancer Antigen CA 125 by the Human Cancer Cell Line NIH:OVCAR-3", <i>Tumor Biology</i> , 22: 77-82.

C25	Manetta, <i>et al.</i> (1989) "Therapeutic Effects of A Radiolabeled Monoclonal Antibody on Human Ovarian Cancer Xenograft in Nude Mice", <i>Gynecologic Oncology</i> , 32: 368-370.
C26	Marth, <i>et al.</i> (1998) "Regulation of the CA 125 Expression in Cultured Human Carcinoma Cells", <i>The Int. J. of Biol. Markers</i> , 13(4): 207-209.
C27	Maughan, <i>et al.</i> (1990) "OC125 Immunoscintigraphy In Ovarian Carcinoma: A Comparison With Alternative Methods of Assessment", <i>Clinical Oncology</i> , 2: 199-205.
C28	McQuarrie, <i>et al.</i> , (1997) "Pharmacokinetics and Radiation Dosimetry of <sup>99m</sup> Tc <sup>m</sup> -Labelled Monoclonal Antibody B43.13 In Ovarian Cancer Patients", <i>Nuclear Medicine Communications</i> , 18: 878-886.
C29	McQuarrie, S.A. (1998) "The Effects of Circulating Antigen on the Pharmokinetics and Radioimmunoscintigraphic Properties of <sup>99m</sup> Tc Labelled Monoclonal Antibodies in cancer Patients", <i>Journal Pharm. Pharmaceut. Sci.</i> , 1(3): 115-125.
C30	Molthoff, <i>et al.</i> (1991) "Human Ovarian Cancer Xenografts In Nude Mice: Characterization arnd Analysis of Antigen Expression", <i>Int. J. Cancer</i> , 47: 72-79.
C31	Nap, <i>et al.</i> (1998) "Immunochemistry of CA 125 Unusual Expression in Normal Tissues, Distribution in the Human Fetus and Questions Around Its Application In Diagnostic Pathology", <i>The International Journal of Biological Markers</i> , 13(4): 210-215.
C32	Nakai, <i>et al.</i> (1993) "Changes in CA125 Release and Surface Expression Caused by Drugs in Uterine Cervix Adenocarcinoma Cells", <i>Annals of Nuclear Medicine</i> , 7(3): 133-139.
C33	Nustad, <i>et al.</i> (1998) "CA 125 - Epitopes and Molecular Size", <i>The Int. J. of Biol. Markers</i> , 13(4): 196-199.
C34	O'Brien, <i>et al.</i> (1998) "More Than 15 Years of the CA 125: What is Known About the Antigen, Its Structure and Its Function", <i>The Int. J. of Biol. Markers</i> , 13(4): 188-195.
C35	Prinsen, <i>et al.</i> (1998) "Biodistribution of 111In-Labelled Engineered Human Antibody CTM01 (HCTM01) In Ovarian Cancer Patients: Influence of Prior Administration of Unlabelled HCTM01", <i>Cancer Immunol. Immunother.</i> , 47: 39-46.
C36	Reinartz, <i>et al.</i> (2004) "Vaccination of Patients with Advanced Ovarian Carcinoma with the Anti-Idiotype ACA125: Immunological Response and Survival (Phase Ib/II)", <i>Clinical Cancer Res.</i> , 10: 1580-1587.
C37	Reinartz, <i>et al.</i> (2003) "Interleukin-6 Fused to an Anti-Idiotype Antibody in a Vaccine Increases the Specific Humoral Immune Response Against CA125 (MUC-16) Ovarian Cancer", <i>Cancer Res.</i> , 63: 3234-3240.
C38	Reinsberg, <i>et al.</i> (1999) "Falsely Low Results in CA 125 Determination Due to Anti-Idiotypic Antibodies Induced by InFusion of [ <sup>131</sup> I]F(ab') <sub>2</sub> Fragments of the OC125 Antibody", <i>Eur. J. Clin. Chem. Clin. Biochem</i> , 31: 323-327.
C39	Rump, <i>et al.</i> (2004) "Binding of Ovarian Cancer Antigen CA125/MUC16 to Mesothelin Mediates Cell Adhesion", <i>The Journal of Biol. Chem.</i> , 279(10): 9190-9198.
C40	Sakahara, <i>et al.</i> (1996) "Effect of Circulatin Antigen on Immunoscintigraphy of Ovarian Cancer Patients Using Anti-CA 125 Monoclonal Antibody", <i>Jpn. J. Cancer Research</i> , 87: 655-661.
C41	Schneider-Gadicke, <i>et al.</i> (1992) "Analysis of Cytotoxicity of <sup>131</sup> I-Labelled OC125 F(ab') <sub>2</sub> on Human Epitheal Ovarian Cancer Cell Lines", <i>Radiotherapy and Oncology</i> , 23: 150-159.
C42	Schorge, <i>et al.</i> (2004) "Osteopontin as an Adjunct to CA125 in Detecting Recurrent Ovarian Cancer", <i>Clinical Cancer Research</i> , 10(10): 3474-3478.
C43	Schlutes, <i>et al.</i> (2003) "Monitoring of Immune Responses to CA125 with an IFN-gamma ELISPOT assay", <i>Journal of Immunological Methods</i> , 279(1,2): 1-15.
C44	Sjovall, <i>et al.</i> (2002) "The Significance of Serum CA 125 Elevation in Malignant and Nonmalignant Diseases", <i>Gynecologic Oncology</i> , 85: 175-178.
C45	Stimpfl, <i>et al.</i> (1999) "Expression of Mucins and Cytokeratins In Ovarian Cancer Cell Lines", <i>Cancer Letters</i> , 145: 133-141.
C46	Sweet, <i>et al.</i> (1989) "Daunorubicin Conjugated to a Monoclonal Anti-CA125 Antibody Selectively Kills Human Ovarian Cancer Cells", <i>Gynecologic Oncology</i> , 34: 305-311.
C47	Verheijen, <i>et al.</i> (1999) "CA 125: Fundamental and Clinical Aspects", <i>Seminars In Cancer Biology</i> , 9: 117-124.
C48	Yin, <i>et al.</i> (2001) "Molecular Cloning of the CA125 Ovarian Cancer Antigen: Identification As A New Mucin (MUC16)", <i>American Society for Biochemistry and Molecular Biology, Manuscript (MI 103554200)</i> 1-28.
C49	Yin, <i>et al.</i> (2002) "Ovarian Cancer Antigen CA125 is Encoded by the MUC16 Mucin Gene", <i>Int. J. Cancer</i> , 98(5): 737-740.

EXAMINER	DATE CONSIDERED
----------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



**LIST OF REFERENCES CITED BY APPLICANT**  
(Use several sheets if necessary)

ATTY DOCKET NO.  
**6750-214-999**

APPLICATION NO  
**10/687,035**

APPLICANT  
**Albone et al.**

FILING DATE  
**October 15, 2003**

GROUP  
**1632**

**U.S. PATENT DOCUMENTS**

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	D01	5,366,866	11/22/94	Xu, et al.			
	D02	5,486,456	1/23/96	Xu, et al.			
	D03	5,650,291	7/22/97	Lee			
	D04	5,871,941	2/16/99	Auersperg			
	D05	6,376,654	4/23/02	Gelber			
	D06	2002-0009451	1/24/02	O'Brien			
	D07	2002-0037287	3/28/02	Gelber			
	D08	2002-0081609	6/27/02	Dillon, et al.			
	D09	2003-0082655	9/9/02	O'Brien			

**FOREIGN PATENT DOCUMENTS**

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	YES	NO
	D10	EP 0 332 651 B2	12/27/96	EPO					
	D11	WO89/01629	2/23/89	PCT					
	D12	WO94/27637	8/12/94	PCT					
	D13	WO96/31539	10/10/96	PCT					
	D14	WO00/36107	6/22/00	PCT					
	D15	WO01/40269	6/7/01	PCT					
	D16	WO01/60860	8/23/01	PCT					
	D17	WO01/70804	9/27/01	PCT					
	D18	WO01/70979	9/27/01	PCT					
	D19	WO01/75177	10/11/01	PCT					
	D20	WO01/85203	11/15/01	PCT					
	D21	WO02/00677	1/3/02	PCT					
	D22	WO02/071928	9/19/02	PCT					
	D23	WO02/074961	9/26/02	PCT					
	D24	WO02/076384	10/3/02	PCT					
	D25	WO02/092836	11/21/02	PCT					

EXAMINER	DATE CONSIDERED
<i>[Signature]</i>	<i>4/24/06</i>

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.